FDA Allows More Input On Off-Label Drug Promotion Limits
The U.S. Food and Drug Administration said Wednesday that it will give the public more time to comment on a review of agency restrictions on the off-label promotion of drugs and...To view the full article, register now.
Already a subscriber? Click here to view full article